Goldman Small Cap Research Issues Research Report On True Nature Holding, Inc.

BALTIMORE, MD / ACCESSWIRE / June 14, 2016 / Goldman Small Cap Research, a stock market research firm specializing in the small cap and microcap sectors, announced today that it has released a research report on True Nature Holding, Inc. (OTCQB: TNTY), which is actively engaged in a roll-up of the highly fragmented, $8 billion dollar compounding pharmacy industry.

True Nature Holding Inc. is actively engaged in a roll-up of compounding pharmacies which have traditionally operated locally but have specialty formulations that may have a larger market. Compounding is a practice in which a licensed pharmacist, or a licensed physician, combines, mixes, or alters ingredients of a drug to create a medication tailored to the needs of an individual patient. This multi-billion dollar market and its broad product utilization are driven by drug shortages, the need for alternative medications or delivery systems for the elderly (liquids versus pills) and those with allergies.

By leveraging product lines and economies of scale, the Company is set for deeper penetration in existing and new markets. It intends to acquire compounding pharmacies that serve both the veterinary and human treatment segments.

In the research report, analyst Rob Goldman discusses the Company’s innovative market strategy and positioning, along with its enviable growth prospects.

Goldman noted, “Newly trading True Nature Holding has hit the ground running, announcing three acquisitions in the past 2 month alone. The Company is actively engaged in a roll-up of the highly fragmented compounding pharmacy industry which has traditionally operated locally but has specialty formulations that may be ripe for a larger market.”

“By leveraging product lines and economies of scale, the Company is set for deeper penetration in existing and new markets. It intends to acquire compounding pharmacies that serve both the veterinary and human treatment segments. This veterinary market could emerge as a sleeper growth segment for the Company. The compounding medicine market for pets is more profitable and not subject to as much regulation as the human treatment segment,” Goldman further commented.

Goldman believes that with no succession plan, limited organic growth and too much regulation, operators are eager to sell to True Nature. They can now join a platform that will offer specialty formulations by region and a national footprint for product sales through online channels.

“With exponential growth through acquisition and potentially high EBITDA margins through economies of scale, True Nature appears primed to reach tens of millions in revenue and millions of dollars in EBITDA next year,” stated the analyst.

About Goldman Small Cap Research: Founded in 2009 by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and microcap stock research reports, articles, daily stock market blogs, and popular investment newsletters. Goldman Small Cap Research is not in any way affiliated with Goldman Sachs & Co.

This press release contains excerpts of our most recently published sponsored research report on True Nature Holding, Inc. which carries a rating and a price target. The information used and statements of fact made have been obtained from sources considered reliable but we neither guarantee nor represent the completeness or accuracy. Goldman Small Cap Research relied solely upon information derived from True Nature Holding, Inc. (“the Company”) authorized press releases or legal disclosures made in its filings with the U.S. Securities and Exchange Commission http://www.sec.gov.

Separate from the factual content of our report about the Company, we may from time to time include our own opinions about the Company, its business, markets and opportunities. Any opinions we may offer about the Company are solely our own, and are made in reliance upon our rights under the First Amendment to the U.S. Constitution, and are provided solely for the general opinionated discussion of our readers. Our opinions should not be considered to be complete, precise, accurate, or current investment advice. Statements herein may contain forward-looking statements and are subject to significant risks and uncertainties affecting results.

A Goldman Small Cap Research report, update, newsletter, article, or press release is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed is to be used for informational purposes only. Please read all associated full disclosures, disclaimers, and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download this sponsored research report or any of our research, view our disclosures and disclaimers, or for more information, visit www.goldmanresearch.com. Goldman Small Cap Research has been compensated by a third party in the amount of $3000 for a research subscription service.

About True Nature Holding, Inc.: True Nature Holding, Inc. (OTCQB: TNTY) plans to acquire compounding pharmacies which have specialty formulations and are seeking a larger market. These pharmacies may serve both the human and veterinary markets. The Company intends to develop a network of compounding pharmacy operations, with both 503(a) and 503(b) facilities, to provide products for not just a single user but also for stocking inventory at doctor’s offices and hospitals.

Learn more about TNTY at http://truenaturepharma.com

Goldman Small Cap Research
Rob Goldman, Analyst
410-609-7100
rob@goldmanresearch.com

SOURCE: Goldman Small Cap Research

ReleaseID: 441098